Rain Oncology (RAIN) Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last twelve months. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings or view top-rated stocks.

12 equities research analysts have issued twelve-month target prices for Rain Oncology's shares. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,910.4% from the stock's current price.
View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts.

Rain Oncology's stock was trading at $8.00 at the start of the year. Since then, RAIN stock has decreased by 89.4% and is now trading at $0.8456.
View the best growth stocks for 2023 here.

Rain Oncology saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 861,800 shares, a decline of 20.2% from the August 15th total of 1,080,000 shares. Based on an average daily volume of 472,700 shares, the short-interest ratio is presently 1.8 days. Currently, 4.3% of the company's shares are sold short.
View Rain Oncology's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RAIN earnings forecast.

Rain Oncology Inc. (NASDAQ:RAIN) issued its earnings results on Thursday, August, 10th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.12.

ETFs with the largest weight of Rain Oncology (NASDAQ:RAIN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Horizon Kinetics Medical ETF (MEDX),

(RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN."

Rain Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Samsara BioCapital LLC (5.60%), Boxer Capital LLC (3.17%), BlackRock Inc. (2.80%), Acadian Asset Management LLC (1.81%), Western Standard LLC (0.95%) and Geode Capital Management LLC (0.89%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Kevin C Tang, Perceptive Advisors Llc and Value Fund L P Biotechnology.
View institutional ownership trends.

Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RAIN stock can currently be purchased for approximately $0.85.

Rain Oncology (NASDAQ:RAIN) has a market capitalization of $30.76 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com.